Effect of angiogenesis inhibitor on soft tissue sarcoma：a Meta-analysis
LIN Feifan1 LI Min2 SHI Xuejun1▲
1.Department of Medical Oncology, Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China;
2.Department of Anesthesiology, Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China
Abstract：Objective To evaluate the clinical effect of angiogenesis inhibitors on the advanced soft tissue sarcoma by Meta-analysis. Methods The database of PubMed, The Cochrane Library, EMbase and CNKI were searched by computer. After selecting the documents and extracting the data according to the inclusion and exclusion criteria, the randomized controlled clinical trials of angiogenesis inhibitors in the treatment of advanced soft tissue sarcoma was selected, and RevMan 5.3 was selected to work out the Meta-analysis. The search time was from begin of database to January 2019. Results 8 RCTs including 991 cases of patients were identified. Meta analysis showed that angiogenesis inhibitors can effectively improve the rate of progress in half a year [OR = 2.44, 95%CI (1.11, 5.38), P = 0.03], objective reaction rate [OR = 1.89, 95%CI (1.15, 3.10), P = 0.01] and disease control [OR = 3.33, 95%CI(2.46, 4.53), P < 0.00 001], there was no significant difference between angiogenesis inhibitors and control group in the half-year survival rate [OR = 0.94, 95%CI(0.66, 1.32), P = 0.71]. Conclusion Angiogenesis inhibitors are effective in the treatment of advanced soft tissue sarcoma, they can effectively improve the rate of progress in half a year, objective reaction rate and disease control and they are valuable in clinical treatment.
[1] Kneisl JS，Coleman MM，Raut CP.Outcomes in the management of adult soft tissue sarcomas [J]. Int J Surg Oncol，2014，110（5）：527-538.
[2] Ducimetiere F，Lurkin A，Ranchere-vince D，et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing [J]. PLoS One，2011，6（8）：e20294.
[3] NG VY，Scharschmidt TJ，Mayerson JL，et al. Incidence and survival in sarcoma in the United States：a focus on musculoskeletal lesions [J]. Anticancer Res，2013，33（6）：2597-2604.
[4] Kampann E，Altendorf-hofmann A，Gibis S，et al. VEGFR2 predicts decreased patients survival in soft tissue sarcomas [J]. Pathol Res Pract，2015，211（10）：726-730.
[5] Rocchi L，Caraffi S，Perris R，et al. The angiogenic asset of soft tissue sarcomas：a new tool to discover new therapeutic targets [J]. Biosci Rep，2014，34（6）：e00147.
[6] Tammela T，Enholm B，Alitalo K，et al. The biology of vascular endothelial growth factors [J]. Cardiovasc Res，2005， 65（3）：550-563.
[7] Gacche RN，Meshram RJ.Angiogenic factors as potential drug target：efficacy and limitations of anti-angiogenic therapy [J]. Biochim Biophys Acta，2014，1846（1）：161-179.
[8] Hensley ML，Miller A，O′malley DM，et al. Randomized phase Ⅲ trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma：an NRG Oncology/Gynecologic Oncology Group study [J]. J Clin Oncol，2015，33（10）：1180-1185.
[9] Mir O，Brodowicz T，Italiano A，et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma（REGOSARC）：a randomised，double-blind，placebo-controlled，phase 2 trial [J]. Lancet Oncol，2016，17（12）：1732-1742.
[10] Ray-coquard IL，Domont J，Tresch-brunee E，et al. Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma：a randomized phase Ⅱ trial [J]. J Clin Oncol，2015，33（25）：2797-2802.
[11] Van Der Graaf WTA，Blay JY，Chawla SP，et al. Pazopanib for metastatic soft-tissue sarcoma （PALETTE）：a randomised，double-blind，placebo-controlled phase 3 trial [J]. Lancet，2012，379（9829）：1879-1886.
[12] Chisholm JC，Merks JHM，Casanova M，et al. Open-label，multicentre，randomised，phase Ⅱ study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma（the BERNIE study） [J]. Eur J Cancer，2017，83（1）：77-84.
[13] 刘佳勇，樊征夫，李舒，等.盐酸安罗替尼胶囊治疗晚期软组织肉瘤Ⅱb期多中心临床试验的单中心数据分析[J].中国肿瘤临床，2018，45（20）：1066-1070.
[14] 张殿宝，康议心，郭艳珍.恩度联合吉西他滨、多西他赛治疗晚期软组织肉瘤的疗效及安全性[J].现代肿瘤医学，2018，26（5）：769-772.
[15] 胡美琴，高琨.阿帕替尼联合AIM方案治疗晚期软组织肉瘤的临床疗效[J].临床药物治疗杂志，2018，16（4）：62-65.
[16] Folkman J，Kalluri R. Cancer without disease [J]. Nature，2004，427（6977）：787.
[17] Ellis LM，Hicklin DJ.VEGF-targeted therapy：mechanisms of anti-tumour activity [J]. Nat Rev Cancer，2008，8（8）：579-591.
[18] Zhao Y，Adjei AA. Targeting angiogenesis in cancer therapy：moving beyond vascular endothelial growth factor [J]. Oncologist，2015，20（6）：660-673.
[19] Bertolini F，Marighetti P，Martin-padura I，et al.Anti-VEGF and beyond：shaping a new generation of anti-angiogenic therapies for cancer [J]. Drug Discov Today，2011， 16（23-24）：1052-1060.
[20] Martin-liberal J，Judson I，Benson C. Antiangiogenic approach in soft-tissue sarcomas [J]. Expert Rev Anticancer Ther，2013，13（8）：975-982.
[21] Mohindra N，Agulink M. Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas [J]. Expert Opin Investig Drugs，2015，24（11）：1409-1418.
[22] Jain RK. Antiangiogenesis strategies revisited：from starving tumors to alleviating hypoxia [J]. Cancer cell，2014， 26（5）：605-622.
2019, Vol. 16 
京公网安备 11010502046598号